NuSirt Biopharma Presenting New Research at American Diabetes Association’s 76th Annual Scientific Sessions

NASHVILLE, Tenn.--()--NuSirt Biopharma will present two posters highlighting its technology, which combines leucine, an essential amino acid, with existing pharmaceuticals, at the American Diabetes Association’s 76th Scientific Sessions. The event is being held at the Ernest N. Morial Convention Center on June 10-14, 2016, in New Orleans, Louisiana.

“We are excited to share recent research related to NuSirt’s technology,” said Joe Cook Jr., president and executive chairman, NuSirt Biopharma. “Both studies being presented show promising data that suggest our technology has potential to become a new treatment option for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).”

The two poster presentations are as follows:

This poster will discuss results from the company’s first completed Phase 2A trial that tested its technology combining leucine and low doses of metformin in patients with Type 2 diabetes. Overall, the trial’s data indicated that patients with the combination therapy showed comparable improvement in several glucose measures coupled with greater improvement in liver enzymes when compared to patients who received full dose metformin.

Although the study did not demonstrate superiority of NuSirt’s leucine and low dose metformin compared to full dose metformin in diabetes, results showed that there was significant synergy when leucine was coupled with metformin as well as dose response. This indication has now provided the company additional scientific support to advance its research for a potential treatment for NAFLD and NASH as well as other metabolic diseases.

This poster will share pre-clinical research testing NuSirt’s patented combination of leucine, low dose metformin and sub therapeutic levels of sildenafil in mice induced with NASH.

Results from the study demonstrated significant potential for the triple combination to reverse NASH in mice. In fact, data showed that the treatment reduced liver fat by 43 percent, liver inflammation by 55 percent and fibrosis by 50 percent.

About Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)

Non-alcoholic fatty liver disease (NAFLD) is a result of fat building up in the liver, preventing the organ’s ability to remove toxins from the blood. It affects up to one-third of the general population. Although there are no known causes for NAFLD, obesity, high cholesterol, diabetes, and high blood pressure are all considered risk factors.

Non-alcoholic steatohepatitis (NASH) occurs in 10 to 30 percent of those with NAFLD. It happens when the liver of a person with NAFLD becomes inflamed, causing severe liver cell damage. Over time, this can result in permanent scarring and hardening of the liver. The consequences of NASH include cardiovascular disease, liver cancer, and liver failure.

About NuSirt Biopharma

NuSirt Biopharma, headquartered in Nashville, Tenn., is dedicated to improving the lives of people living with chronic metabolic diseases. The company has a unique technology platform that uses patented combinations of leucine, an essential amino acid, with existing human medicines to target diseases that may be addressed by activating sirtuin pathways. In pre-clinical studies, these combinations have shown promise in preventing and treating metabolic diseases by enabling new applications for existing pharmaceuticals and enhancing their effectiveness. For more information, please visit


For NuSirt Biopharma
Nicole Cottrill, 615-610-0305

Release Summary

NuSirt Biopharma will present two posters at the American Diabetes Association’s 76th Scientific Sessions suggesting that its technology has potential to become a new treatment option NAFDL and NASH.


For NuSirt Biopharma
Nicole Cottrill, 615-610-0305